Evidence / 2023
guideline
The Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder
May T, Birch E, Epstein A, et al. (2023). Australian & New Zealand Journal of Psychiatry.
- Population
- People with ADHD; guideline development stakeholders including lived experience
- Sample
- Guideline methods paper
- Condition
- ADHD
- Medication focus
- ADHD treatments as reviewed in the parent guideline
- Jurisdiction
- Australia
- Last reviewed
- 1 September 2026
- PMID
- 37254562
Plain-language finding
Describes the development of the Australian ADHD guideline, including lived-experience priorities, identification, diagnosis and treatment aims.
Important limitation
This is a methods and summary paper for the guideline, not an original treatment trial.
Why we cite this
Peer-reviewed description of the Australian ADHD guideline and its development process.
adhd · guideline · australia · lived-experience
Supported by clinical guidelines, regulatory information, systematic reviews, or well-established pharmacological knowledge. Still describes populations, not an individual.